Search results
Oct 20, 2016 · Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.
Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness. [2] [4] For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment. [4] . In Chagas disease it is a second-line option to benznidazole. [5] . It is given by mouth. [2]
- C₁₀H₁₃N₃O₅S
- By mouth
- Lampit
LAMPIT (nifurtimox) tablets, for oral use Initial U.S. Approval: 2020 . INDICATIONS AND USAGE ----- LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients...
- 780KB
- 19
Nifurtimox is an antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi.
Medscape - Indication-specific dosing for Lampit (nifurtimox), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...
Dec 8, 2020 · 08 December 2020. Cite. Permissions. Share. Extract. Nifurtimox is a nitrofuran antiprotozoal. Class: 8:30.92 • Antiprotozoals, Miscellaneous (AHFS primary) Brands: Lampit®. Uses. Nifurtimox has the following uses: ... Dosage and Administration. General. Nifurtimox is available in the following dosage form (s) and strength (s): ... Dosage.
The recommended oral dose for adults is 8–10 mg/kg body weight per day. The dosage for adolescents is 12.5–15 mg/kg per day and for children 1–10 years of age it is 15–20 mg/kg per day. Nifurtimox should be given in four divided doses each day, and therapy should be continued for 90–120 days. Adverse Effects:
